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Increased expression of MMP-2, MMP-9 (type IV collagenases/ Alport syndrome (AS) is a group of genetic disorders
gelatinases), and MT1-MMP in canine X-linked Alport syndrome resulting from mutations in collagen IV genes. The patho-
(XLAS). logic hallmark of the disease is irregular thickening, thin-Background. Alport syndrome is a group of genetic disor-
ning, and splitting of the glomerular basement membraneders resulting from mutations in either the 3(IV), 4(IV)
(GBM) revealed by electron microscopic examinationor 5(IV) collagen chains. The disease is characterized by a
progressive glomerulonephritis, usually associated with a high- of renal tissue. Patients with AS frequently have progres-
frequency specific sensorineural hearing loss, dot and fleck sive high-frequency sensorineural hearing loss, retinal
retinopathy, and lens abnormalities. Dogs with naturally oc- flecks, and lens abnormalities in addition to the renalcurring genetic disorders of basement membrane collagen (type
phenotype [1]. In humans, most cases of AS are causedIV) may serve as animal models of Alport syndrome. In this
by mutations in the collagen 5(IV) gene, which residesstudy, a well-characterized naturally occurring canine model
was employed to demonstrate a potential role for matrix metal- on the X chromosome, and thus results in a severe domi-
loproteinases (MMPs) in Alport renal disease pathogenesis. nant form of the disease in males, and a less severe pheno-
Methods. Adolescent male dogs that developed renal failure type in females due to random X chromosome inactiva-were euthanized and necropsied. Clinicopathologic features of
tion resulting in phenotypic mosaicism [2, 3]. Autosomal-the disease were characterized, and kidneys from normal and
recessive forms of AS are less common (about 15% ofAlport dogs were analyzed by gelatin zymography, Western blot-
ting, in situ zymography, immunohistology, and by reverse tran- cases), and result from mutations in the collagen 3(IV)
scription polymerase chain reaction (RT-PCR) for expression and 4(IV) genes [4, 5]. In human AS, the mutations in
of MMP-2, MMP-9, and membrane type 1-MMP (MT1-MMP).
3(IV), 4(IV), or 5(IV) chains of type IV collagenResults. Affected dogs developed proteinuria and rapidly
are often associated with a loss of these chains from theprogressive juvenile-onset chronic renal failure. The activities
GBM, leaving only collagen 1(IV) and 2(IV) chains,of MMP-2 and MMP-9 were significantly induced in Alport
kidney. In situ zymography confirmed elevated active metallo- although exceptions have been noted [6]. Two gene knock-
proteinases in kidney cryosections of affected dogs. The mRNAs out mouse models and a random transgene insertion mouse
encoding MMP-2, MMP-9 and MT1-MMP were also increased model for autosomal Alport syndrome have been de-in Alport dogs suggesting that elevated expression of MMPs
scribed [7–9]. Three different dog models, including tworeflects events in the progression of Alport syndrome in dogs.
with X-linked inheritance and one with autosomal inher-Conclusion. Elevated expression of MMP-2, MMP-9, and
MT1-MMP is observed in fibrotic renal cortex from X-linked itance, have been described [10–13]. All of these models
Alport syndrome dogs. These findings suggest that MMPs may are deficient in collagen 3(IV), 4(IV), and 5(IV)
play an important role in matrix accumulation associated with chain deposition in the GBMs, and all culminate in glo-progressive renal scarring in this model.
merular and interstitial fibrosis.
Clinicopathologic studies of various glomerular dis-
Key words: Alport syndrome, fibrosis, matrix metalloproteinase. eases have demonstrated that tubulointerstitial pathol-
ogy correlates with the degree and progression of renalReceived for publication July 30, 2002
impairment, regardless of the type and anatomic originand in revised form December 5, 2002
Accepted for publication January 3, 2003 of the inciting injury [14, 15]. The interstitial matrix de-
posited in the scarred kidney is produced by resident 2003 by the International Society of Nephrology
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cells, including activated fibroblasts and tubular epithe- scores were based on a semiquantitative assessment of
the extent of cortical interstitial fibrosis observed in 3mlial cells with a fibrinogenic phenotype [16]. A net accu-
mulation of matrix may result from changes in synthesis, thick, hematoxylin and eosin–stained sections of kidney
from each dog. Sections were assigned scores on a scaledegradation, or both. Changes in synthesis of matrix
components in fibrosis have been addressed; however, from 0 to 3, with 0 representing normal kidney with
scant to no interstitial connective tissue, and 1 to 3the contributing role of matrix turnover has not received
similar attention. representing progressively increasing severity of intersti-
tial fibrosis. Fibrosis scores of 3 were representativeDevelopmental and homeostatic remodeling of the
extracellular matrix (ECM) is a highly regulated process of the upper limit of severity of renal cortical fibrosis
generally observed in male Alport dogs necropsied atorchestrated by a family of zinc-containing, calcium-depen-
dent, secreted neutral proteases known as the matrix metal- the standardized end point used in this study. For our
studies, necropsy specimens of kidney from five Alportloproteinases (MMPs). This family of enzymes, which now
contains over 25 members, can collectively degrade all dogs and five normal dogs were analyzed.
structural proteins of the ECM, including interstitial col-
Tissue processinglagens (I, II, III and V), basement membrane collagens
(IV), fibronectin, laminin, proteoglycans and elastin. The Necropsies were performed after euthanasia and a
portion of renal cortex was formalin-fixed and later par-MMPs include collagenases, gelatinases, stromelysins,
macrophage metalloelastase, matrilysin, and membrane- affin-embedded, sectioned, and stained for light micro-
scopic examination. Another portion was immediatelytype MMPs. They are regulated at the level of gene
transcription by latent proenzyme activation and are in- immersed in liquid nitrogen and kept at80C until use.
For further processing, tissues were thawed, weighed, andhibited by a group of inhibitor proteins known as tissue
inhibitors of MMP, which consist of four family members homogenized in Tris buffer (0.5 mol/L Tris-HCl, pH 7.5,
containing 200 mmol/L NaCl and 0.2% Triton X-100),(TIMP-1 to TIMP-4) [17, 18].
The relative balance of MMPs and TIMPs is thought centrifuged, and the supernatants were aliquoted and
stored at –80C. The protein content in the supernatantsto determine the rate of ECM turnover. An imbalance in
these ratios can contribute to the progression of some was determined using the micro BCA assay kit according
to the manufacturer’s instructions (Pierce Biochemicals,pathologic disorders, including tumor invasion and meta-
stasis, arthritis, fibrotic diseases, atherosclerosis, and em- Rockford, IL, USA) and stored at –20C until used.
physema [19]. A highly regulated balance of active MMPs
Gelatin zymographyand TIMPs is maintained during normal tissue metabo-
lism. To date, there have been no in vivo studies of the Substrate gel electrophoresis (zymography) was per-
formed to identify whether the extracts contained MMPcontribution of MMPs and TIMPs to the development
of fibrosis in AS. Using dogs with X-linked Alport syn- activity and to identify the enzymes involved. The gela-
tin-degrading activity was examined by electrophoresisdrome, we studied the expression of MMP genes and histo-
logic evidence of kidney fibrosis. The results of our study on an 8% sodium dodecyl sulfate polymerase acrylamide
gel electrophoresis (SDS-PAGE) containing gelatin (1.0revealed a strong correlation between MMP gene expres-
sion, MMP gelatinase activity, and histopathologic evi- mg/mL) without prior heating or reduction as described
[20, 21]. Prestained SDS-PAGE protein standards (Bio-dence of fibrosis, suggesting that deregulated matrix re-
modeling may contribute to the pathology of the disease. Rad Laboratories, Richmond, VA, USA) and condi-
tioned media from human HT1080 cells, which contain
MMP-2 and MMP-9, were run in parallel to determine
METHODS
the molecular weights of gelatinases present in kidney
Dogs tissue extracts. After electrophoresis, the gels were washed
in 2.5% Triton-X 100 and incubated in 50 mmol/L Tris-Animals were from a colony of dogs originally referred
to as the Navasota kindred, which is on a mixed back- HCl buffer, pH 7.5, containing 0.15 mol/L NaCl, 10
mmol/LCaCl2, and 0.02% NaN3. Gels were stained withground [11]. Recently, a 10 base pair deletion has been
identified in exon 9 of the type IV collagen 5 gene, Coomassie Brilliant Blue R250 and destained. Gelatino-
lytic activity of each gelatinase is evident as a clear bandconfirming these dogs serve as a genetic model for XLAS
(Cox et al, unpublished). Progression of renal disease in against the blue background of stained gelatin. The addi-
tion of molecular weight markers and MMP-2 standardAlport dogs was monitored to a standardized end point,
serum creatinine 5.0 mg/dL (normal reference range, to the gels facilitated identification of the enzymes. The
accuracy and sensitivity of the zymographic technique0.5 to 1.5 mg/dL) or onset of uremic symptoms (anorexia
and vomiting on 2 consecutive days), whereupon each for determining protease levels was analyzed by running
different amounts of purified MMP-2 and MMP-9. Thisdog was necropsied. Normal dogs used as controls were
unaffected littermates of Alport dogs. Renal fibrosis confirmed the linearity of zymography (not shown).
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In order to determine whether clarified zones were lenses configured with a SpotRT digital camera and Im-
age Pro-plus software (Tokyo, Japan). Tissue sectionsdue to MMPs or to serine or aspartic proteases, duplicate
gels were incubated in proteolysis buffer with addition were reacted with preimmune serum and then with sec-
ondary antibody as a control for background immuno-of appropriate inhibitors for the enzyme class. The inhib-
itors used were 10 mmol/L ethylenediaminetetraacetic staining.
acid (EDTA) for MMPs; 1.0 mmol/L phenylmethylsulfo-
Reverse transcription polymerase chain reactionnyl fluoride (PMSF) for serine proteases, and 5.0 mol/L
(RT-PCR) analysispepstatin A for acid and aspartic proteases.
Semiquantitative analysis of MMP-2, MMP-9, and
Detection of gelatinolytic activity by film in situ MT1-MMP transcripts was performed by RT-PCR as de-
zymography (FIZ) scribed previously [21]. Briefly, total RNA was isolated
using Trizol (GIBCO BRL, Gaithersberg, MD, USA)The gelatinolytic activity was also detected by FIZ
using cross-linked gelatin film (gelatinolytic-type film) ac- according to the manufacturer’s instructions. Total RNA
(5 g) was reverse transcribed by using Superscript IIcording to manufacturer’s instructions (Fuji Photo Film
Co., Ltd., Tokyo, Japan) with modifications. Briefly, sam- with oligo dT primers (GIBCO BRL, Gaithersberg, MD,
USA)ples of kidney were embedded without fixation in Tissue-
Tek 22-oxacalcitriol (OTC) compound (Sonkura Fine- The reverse transcribed cDNA was used in each PCR,
in a total volume of 50 uL, with specific primers for targettek, Torrance, CA, USA). These frozen blocks were then
sliced sequentially using a cryostat microtome to prepare molecules [MMP-2, MMP-9, MT1-MMP, and glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH)]. Semiquan-serial frozen-thin sections (6 um thickness). These thin
sections were placed on a polyethylene terephthalate titation of MMP-2, MMP-9, and MT1-MMP cDNAs was
performed using densitometry and comparison to GAPDHbase film (Fuji Photo Film Co., Ltd.), coated with cross-
linked gelatin of 7 m in thickness. The films with sec- (internal standard) from the same sample after using an
image analysis system (Imagequant Software, Moleculartions were incubated for 12 hours at 37C in a humidified
chamber and stained with 1% Amido Black 10B in 70% Dynamics, Sunnyvale, CA, USA). The intensity of each
band was expressed in arbitrary units.methyl alcohol, 10% acetic acid, and 10% glycerol for
10 minutes, destained in 70% methyl alcohol, 10% acetic The oligonucleotide primer pairs used were as follows:
canine MMP-2 (GeneBank accession no. AF177217), 5-acid, and 10% glycerol for 10 minutes and kept in 20%
glycerol for 20 minutes. The sections were cover-slipped, GCC CCA AAG AGA GAT GCA ACC TAT-3 (sense)
and 5-CGG CCA AAG TTG ATC ATG ATG TC-3sealed, and imaged. The gelatin in contact with the proteo-
lytic areas of the sections was digested, and thus negative (antisense); human MMP-9 (GeneBank accession no.
J05070), 5-GGT CCC CCC ACT GCT GGC CCT TCTstaining indicated zones of enzymatic activity. To confirm
the specificity of in situ zymography, frozen sections were ACG GCC-3 (sense) and 5-GTC CTC AGG GCA CTG
CAG GAT GTC ATA GGT-3(antisense); canine MT1-also placed on gelatin-coated films containing 1,10-phen-
anthroline (gelatinase inhibitor [GI] films), which is known MMP (GeneBank accession no. AF097638), 5-TGT TTG
ATG AAG CTT CTC TGG A-3 (sense) and 5-TCCto inhibit the activity of MMPs.
AGT ATT TGT TCC CCT TGT A-3 (antisense); and
Immunofluorescence evaluations human GAPDH (Genebank accession no. M33197), 5-
GGT GAA GGT CGG AGT CAA CGG ATT TGGKidneys were embedded in Tissue-Tek OTC aqueous
compound. They were frozen and sectioned at 4 m on TCG-3 (sense) and 5-GGA TCT CGC TCC TGG AAG
ATG GTG ATG GG-3 (antisense). Each PCR was car-a cryostat. Tissue sections were fixed for 10 minutes in
acetone. After washing the slides in phosphate-buffered ried out at various numbers of cycles under identical
conditions to optimize the reactions. The amplified prod-saline (PBS), they were incubated in a moist chamber
with the appropriate dilution of primary antibodies. The ucts were identified by electrophoresis of an aliquot on
2.0% agarose gel stained with ethidium bromide, visual-antibodies used were anti-human MMP-2, MMP-9 (a gift
from Dr. Z. Gunza-Smith, Miami, FL), and rabbit poly- ized by ultraviolet transillumination, and photographed.
DNA bands were analyzed by computer-assisted densi-clonal anti-MT1-MMP antibodies (Calbiochem, La Jolla,
CA, USA). After washing, the slides were incubated with tometric scanning of these images using an image analysis
system (Imagequant Software, Molecular Dynamics).affinity-purified fluorescein isothiocyanate (FITC)-con-
jugated goat antirabbit immunoglobulin G (IgG) (Vector The intensity of each amplified product increased with
the increasing number of PCR cycles. The number of PCRLaboratories, Burlingame, MA) and mounted with Vec-
tashield mounting media for fluorescence (Vector Labo- cycles for each product was determined to lie in the
linear range with respect to specific band intensity. Theratories). The sections were cover-slipped, sealed, and
imaged. Images were collected using an Olympus (Tokyo, PCR cycling parameters for MMP-2 were as follows:
initial denaturation temperature at 94C for 10 minutesJapan) BH-2 fluorescence microscope with PlanAPO
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Fig. 1. General morphology of renal cortex from X-linked Alport syndrome (XLAS) dogs typical of those used in this study. Tissue was embedded
in paraffin, cut at 3 m, and stained using hematoxylin and eosin. Fibrosis scores, determined as described in the text, are indicated. C is normal.
Table 1. Animals used in the study specific cycle numbers were as follows: for MMP-9, 30
cycles; for MT1-MMP, 34 cycles; and GAPDH, 25 cycles.Age at Serum Renal
Sample necropsy creatinine fibrosis In each instance, the constitutively expressed GAPDH
number Status Gender months mg/dL score mRNA was used as an internal standard for RT-PCR.
1 Normal Male 12 1.1 0 The PCR procedure was repeated at least three times
2 Normal Male 7 1.1 0
for each sample. No PCR product was observed in sam-3 Normal Male 7 1.0 0
4 Normal Male 11 1.1 0 ples in which either cDNA or reverse transcriptase was
5 Normal Male 11 1.2 0 omitted. To control for sample variation due to handling,6 Affected Male 11 5.0 2
band intensities for each unknown were normalized to7 Affected Male 13 5.5 2
8 Affected Male 8 5.0 3 band intensities for GAPDH, which was amplified in
9 Affected Male 7 4.9 3 parallel.10 Affected Male 11 5.1 3
DNA sequencing
The MMP-2, MMP-9, MT1-MMP, and GAPDH frag-
ments amplified from XLAS and control kidneys by PCR(one cycle), annealing at 94C for 60 seconds, 60C for
were purified using Multiscreen PCR. The resultant60 seconds, and 72C for 90 seconds (32 cycles), and
DNA was subjected to a cycle sequencing reaction usingfinal extension at 72C for 10.0 minutes (final cycle).
the ABI Prism dye-labeled terminator reagent (PE Bio-For amplification of the other mRNA transcripts, the
systems, Foster City, CA, USA), according to the proto-parameters were kept constant except for the cycle num-
ber, which were optimized for each pair of primers. The col provided by the manufacturer. The reaction product
Rao et al: MMPs in canine Alport syndrome1740
Fig. 2. Immunofluorescence staining for matrix metalloproteinases (MMP-2 and MMP-9) and membrane type 1 MMP (MT1-MMP) in normal
and X-linked Alport syndrome (XLAS) renal cortex. Cryosections from normal (A, B, and C) and XLAS (D, E, and F ) dogs were subjected to
immunofluorescence immunostaining using antibodies specific for the indicated MMP. Cryosections (G, H, and I ) were reacted with preimmune
serum as a control for background immunostaining. Bar is 100 m.
was analyzed with an ABI automated DNA sequencer, TBST and were incubated with peroxidase-conjugated
secondary rabbit antibody. Finally, the color was devel-model 377 (Applied Biosystems, Palo Alto, CA, USA).
oped using diaminobenzidine and hydrogen peroxide as
Western blot analysis described [22].
The specificity of MMP-2, MMP-9, and MT1-MMP
Data presentation and statistical analysisantibodies used in the immunohistochemical analyses
was characterized by Western blot analysis. The tissue Data are expressed as mean  SD. Differences be-
tween means were tested for significance using Studentextracts were subjected to standard 8% SDS-PAGE un-
t test. Differences were considered significant at the levelder reducing conditions as described earlier [21]. Pro-
of P 	 0.05.teins were then electrophoretically transferred onto a
nitrocellulose membrane, blocked with 5% nonfat dry
milk in Tris-buffered saline plus 1% Tween-20 (TBST)
RESULTS
(Bio-Rad, Hercules, CA, USA), followed by incubation
Clinicopathologic evaluationswith diluted rabbit polyclonal antibodies (MMP-2, 1:300;
MMP-9, 1:300; and MT1-MMP, 1:500) overnight at 4C. The Alport dogs manifested progressive renal disease
typical of that previously described in males from thisThe membranes were washed again three times with
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kindred [11]. Affected dogs used in this study developed
persistent proteinuria [urine protein to creatinine (UPC)
ratio 
0.5 then and thereafter] at 3 to 5 months of age.
Onset of azotemia (serum creatinine1.6 mg/dL) occurred
at 4 to 8 months of age, and their renal failure progressed
to the standardized end point at 7 to 13 months of age.
Normal dogs did not exhibit proteinuria (UPC 0.5)
and were not azotemic. Interstitial fibrosis was not ob-
served in the kidneys of normal dogs. However, the tubu-
lointerstitium of the renal cortex of all Alport dogs was
expanded by fibrous connective tissue admixed with
mixed mononuclear inflammatory cells typical of the
chronic inflammatory renal changes associated with this
syndrome. Characteristic histology of renal cortex from
normal dogs and from Alport dogs that were scored at
1, 2, and 3 are provided in Figure 1. Ages at nec-
ropsy, serum creatinine levels, and renal fibrosis scores
of dogs used in this study are summarized in Table 1.
Immunofluorescence microscopy for MMP-2, MMP-9,
Fig. 3. Western blot analysis of matrix metalloproteinases (MMP-2and MT1-MMP
and MMP-9) and membrane type 1 MMP (MT1-MMP) in normal and
We examined MMP-2, MMP-9, and MT1-MMP ex- X-linked Alport syndrome (XLAS) tissue extracts. C is tissue extracts
from unaffected; and A is from an XLAS dog with a fibrotic score ofpression in normal and XLAS renal cortex. Representa-
3. Results demonstrated that the antibodies used in the immunofluo-tive fields from normal and XLAS dogs with a fibrosis
rescence studies are specific for the respective MMPs in dog tissues.
score of 2 are shown in Figure 2. No obvious qualitative
differences were observed when comparing sections
from animals with a fibrosis score of 2 or 3. Expression dog kidney extracts from necropsy samples was analyzed
of MMP-2 and MMP-9 in controls is weakly evident in by gelatin zymography. Figure 4 is provided to validate
the tubular epithelial cells (Fig. 2A and B). In Alport the specificity of the assay to detect latent and active forms
dogs, however, brightly stained cells are evident in the of the MMPs. Extracts from XLAS kidney contained sev-
interstitial space. MMP-9 also appears to accumulate in eral protease activities at molecular weights of 92, 84,
the basement membranes and the interstitial matrix near 72, and 64 kD. The upper gelatinolytic bands represent
clusters of brightly stained cells (Fig. 2E). MT1-MMP the 92 kD (latent or proform) and 88 kD (active form)
expression is again very low in the tubular epithelial
MMP-9 species, whereas the lower gelatinolytic bandscells in normal dog kidneys; however, in XLAS kidneys,
represent the 72 kD (latent or proform) and 64 kD (ac-elevated immunostaining is observed at the interface
tive form) MMP-2 species. Standards, which are superna-between the tubular epithelial cells and the tubular base-
tants from human fibrosarcoma (HT1080) cells, are pre-ment membranes. This cell surface localization is consis-
dominantly the latent forms of MMP-2 and MMP-9.tent with the fact that MT1-MMP is a membrane bound
The gelatinase activity was completely inhibited byproteolytic activator for MMP-2 [23]. No immunostain-
EDTA, a chelating agent, confirming that the observeding was observed when tissue sections were incubated
bands were the result of zinc-dependent metalloprotei-with preimmune serum (Fig. 2 G to I), indicating that the
nase activity. The gelatinase bands on the zymogramobserved immunostaining is not due to nonspecific binding.
were not inhibited by PMSF, an inhibitor of serine prote-Since none of these antibody preparations have pre-
ases, or pepstatin A, an inhibitor of aspartic proteases.viously been used to detect MMPs in dog tissues, it neces-
sary to evaluate their specificity. To test for this, tissue Analysis of gelatinase activity in the renal cortex of
extracts from a control and Alport dogs were subjected XLAS dogs
to Western blot analysis. The blots developed with the
Gelatin zymography was performed using extracts ofantibodies demonstrated a single band for each antibody
renal cortex from control and XLAS dogs. Extracts werewith the predicted molecular size (Fig. 3). This confirms
derived from necropsy specimens taken from individualsthat the antibodies are indeed specific, and cross-reactive
with either moderate fibrosis score (2) or severe fibrosiswith the respective dog MMPs.
score (3). The results in Figure 5 illustrate that significant
Detection of MMP activity by gelatin zymography differences in the levels of MMP-2 and MMP-9 were evi-
dent in the XLAS necropsy kidney extracts when com-Proteolytic activity of two forms of type IV collagenase
(72 kD, MMP-2; 92 kD, MMP-9) in control and XLAS pared to normal dogs. The active forms of both MMP-2
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Fig. 4. Specificity of gelatin zymography for
detecting matrix metalloproteinase (MMP)
activity in tissue extracts. Lane 1, media from
human fibrosarcoma cells (positive control);
lane 2, tissue extract from unaffected; and lane
3 from an X-linked Alport syndrome (XLAS)
dog with a fibrosis score of 3. Both latent
and active forms of MMP-2 and MMP-9 are
denoted. Labels below the lanes indicate what
was added to the gel incubation buffer, illus-
trating that the gelatinase activity is inhibited
by ethylenediaminetetraacetic acid (EDTA),
which is an inhibitor of MMPs, but not by phe-
nylmethylsulfonyl fluoride (PMSF) or pepsta-
tin A, demonstrating that activity is not due
to serine or aspartate proteases.
Fig. 5. Interstitial disease in the X-linked Alport syndrome (XLAS) dogs is associated with markedly elevated matrix metalloproteinases (MMP-2
and MMP-9) activity. Sample numbers are reflecting animals described in Table 1. (A ) Gelatin zymography for MMP-2 and MMP-9 proteolytic
activity in necropsy tissue extracts from normal versus XLAS dogs. Quantitative analysis of MMPs. Gelatin zymograms were analyzed by scanning
densitometry and expressed as arbitrary units to produce histograms. (B ) The activity of total MMP-2 and MMP-9 are elevated in XLAS dogs
compared to unaffected dogs. Total gelatinolytic activity represents the sum of both MMP-2 and MMP-9 activities. (C ) Latent and active MMP-9
for individual samples are shown. (D ) The values for total, MMP-2, and MMP-9 (both latent and active MMP-9 are shown) as mean and standard
deviation for control and Alport dogs. The zymogram shown is representative of three independent experiments. *Statistical significance compared
with control kidney extracts at P 	 0.001.
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Table 2. Summary of changes in matrix metalloproteinase (MMP) activity and mRNA levels relative to that observed in normal dogs
MMP activity mRNA expression
Sample Serum creatinine Fibrosis
number mg/dL score MMP-2 MMP-9 MMP-2 MMP-9 MT1-MMP
6 5.4 2 6.80.5 75.38.2 1.70.2 17.91.9 2.30.3
7 5.0 2 6.50.7 68.77.5 2.00.3 17.51.8 2.50.2
8 4.9 3 7.40.8 87.88.9 2.10.3 21.12.2 2.50.3
9 5.3 3 7.40.8 82.59.1 2.20.3 19.62.0 2.70.3
10 5.2 3 7.60.8 98.610.1 1.90.2 19.21.9 2.80.4
Data are expressed as the mean of three independent measurements with standard deviations. MTI-MMP is membrane type 1 matrix metalloproteinase.
and MMP-9 were observed only in XLAS tissue extracts predicted size for selected cDNA fragments encoding
(Fig. 5A). Zymographic bands were quantified by scan- the MMPs and GAPDH, a housekeeping gene that was
ning densitometry and the data analyzed using Image used to control for cDNA loading in the PCR reactions.
Quant software (see Methods section) and expressed as Sequencing of amplified cDNAs from control and XLAS
arbitrary units of lysis. There was a significant increase indicated 100% homology with the published sequences
in the levels of both MMP-2 and MMP-9 in XLAS dogs validating that the amplified products were indeed spe-
in comparison to controls (P 	 0.001) (Fig. 5B). Fold cific (not shown). The most dramatic induction of MMP
induction was remarkably high, especially for MMP-9, mRNA expression in XLAS was that for MMP-9 (Fig.
and did not vary substantially in samples derived from 7A, middle panel), consistent with the data obtained
animals with fibrosis scores of 3 compared to 2 (an through gelatin zymography. RT-PCR amplification of
average of 89-fold versus 72-fold, respectively, for MMP-9, MMP-9 produced a cDNA of the expected size, which
and 7.5-fold versus 6.6-fold, respectively, for MMP-2, see was barely detectable in controls but was significantly
Table 2). Active MMP-9 is seen only in affected animals increased (19-fold on average, see Table 2) in XLAS
and not in controls (Fig. 5C). (P 	 0.001). The relatively low levels of MMP-9 amplifi-
cation product in controls was not the result of the quality
In situ zymography for the detection of gelatinase
or quantity of mRNA because the presence of intactactivity by FIZ
mRNA, as well as equivalent loading of reverse tran-
In situ zymography using gelatin films (gelatinolytic scribed message in the PCR reactions was demonstrated
films) on cryosections revealed that strong gelatinolytic by amplification of GAPDH mRNA (Fig. 7A, lower
activity is present in specimens from XLAS dogs, but panel). Amplification of MMP-2 (Fig. 7A, upper panel)
very little or no activity was recognized in the normal dogs confirms expression in both control and XLAS dogs and
(Fig. 6). The region where gelatinolysis occurred was elevated expression (twofold on average, see Table 2)
observed as white to pale blue. The gelatinolytic activity in XLAS dogs as compared to control (P 	 0.001). The
in the cryosections was almost completely inhibited on relative expression of MMP-2 and MMP-9 specific
sections that have been incubated on the film containing mRNA transcripts in XLAS as determined by densito-
1,10-phenanthroline (GI film), a broad MMP inhibitor.
metric analysis of RT-PCR is given in Figure 7C. TheseThe FIZ gelatin films employed in this assay have been
results were qualitatively in agreement with zymographyshown to detect only the active isoforms of the MMPs
(gelatin and in situ) and immunofluorescence analysis.[24], confirming that a marked increase in overall metal-
Fold induction of mRNA versus gelatinolytic activity,loproteinase activity is evident in the Alport renal cortex.
however, revealed some interesting similarities. Fold in-Furthermore, this activity appears predominantly in the
duction of MMP-2 and MMP-9 gelatinolytic activity wasinterstitial space, and not in the glomeruli (denoted as
greater than that for MMP-2 and MMP-9 mRNA. TheG in Fig. 6).
ratio for fold induction (in XLAS versus control samples)
of enzyme activity to mRNA, on average, is between 3Detection of mRNA for MMP-2, MMP-9,
and MT1-MMP and 4 to 1 for both MMP-2 and MMP-9. Gelatinolytic
activity and specific mRNA levels for the MMPs wereRT-PCR analysis was used to determine whether the
not significantly different for samples taken from animalsinduction of MMP-2 and MMP-9 protein was secondary
with a fibrosis score of 2 compared to 3.to the increased expression of MMP-2 and MMP-9 mRNA
Transcripts for MT1-MMP mRNA were also analyzedtranscripts in XLAS kidneys. RNA was isolated from a
by RT-PCR and found to be consistently and significantlyportion of the same necropsy specimen employed in the
elevated (2.6-fold on average, Figure 8 and Table 1) ingelatin zymography experiments. Corresponding sample
XLAS-derived samples relative to controls (P 	 0.001).numbers were derived from the same animals employed
These data reflect elevated MT1-MMP protein observedfor gelatin zymograms (Fig. 5). The primers selected
for amplification produced only a single product of the by immunofluorescence (Fig. 2 C and F).
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nents, including interstitial and basement membrane col-
lagen and glycoproteins and play an important role in
various physiologic and pathologic conditions [25, 26].
Here we show that the MMP-2, MMP-9, and the mem-
brane-bound proteolytic activator for the MMPs, MT1-
MMP, are all up-regulated in the renal cortex of XLAS
dogs. Induction is apparent at both the level of mRNA
and enzyme activities. Further, in situ zymography re-
veals the presence of active metalloproteinase in tissue
sections of XLAS renal cortex, demonstrating that the
elevated expression translates to elevated metalloprotein-
ase activity in the organ. Combined, these data provide
compelling evidence suggesting a role for MMPs in aber-
rant matrix remodeling associated with interstitial fibro-
sis in the canine XLAS model. An earlier study examined
the role of MMP-9 in glomerular pathogenesis in a mu-
rine Alport model and concluded that it did not influence
disease progression. This study, however, did not address
tubulointerstitial disease [27].
The regulation of kidney ECM remodeling during nor-
mal tissue metabolism and its dysregulation in kidney
diseases may result from a complex interplay of MMP
transcriptional regulation, proenzyme activation, and in-
hibition by TIMPs. In interstitial fibrosis, the primary
insult initiates a sequence of events starting with the
influx of a variety of inflammatory cells, including mono-
cytes. These cells produce a variety of cytokines, growth
factors and other mediators that presumably function to
repair the damaged tissue and modulate expression of
the MMPs [28]. Some MMPs, including MMP-2, MMP-3,
MMP-9, and metalloelastase, are potentially capable of
disrupting the kidney architecture by virtue of their spec-
ificity for various components of basement membrane,
thus enabling further infiltration of inflammatory cells
into the kidney and thereby setting into motion the dys-
regulated matrix remodeling that follows. Recently, we
have demonstrated significantly elevated levels of MMP-2
and MMP-9 in a mouse model for AS, which progres-
sively develops interstitial fibrosis between 4 and 8 weeks
after birth. Further studies also demonstrated that the
tissue monocytes, independent of myofibroblasts, drive
Fig. 6. In situ gelatin zymography using gelatin films demonstrated tubular atrophy in the Alport mice [29]. The data pre-
strong gelatinolytic activity in the X-linked Alport syndrome (XLAS) sented here are the first to demonstrate differential ex-dogs (Alport) as compared to control (Control). In this particular field,
pression of gelatinases and MT1-MMP genes in canineactivity was in the interstitial space surrounding the glomerulus (G).
The glomerulus itself, however, was negative for active metalloproteinase. XLAS, an animal model for human XLAS. Our results
The gelatinolytic activity is almost completely blocked in samples incu- suggest that differential MMP expression may contributebated on film containing 1,10-phenanthroline (Alport GI) indicating
to the molecular pathogenesis of the disease.that the gelatinolytic activity is attributable to MMPs.
We show that XLAS extracts contained activated forms
of MMP-2 and MMP-9 but the mechanism for the activa-
tion is not clear. MMPs are secreted as inactive latent
DISCUSSION precursors (zymogens) and their activation is a prerequi-
Remodeling of ECM accompanies many physiologic site to their functioning in vivo [25, 26]. Activation of
and pathologic processes. The MMPs constitute a multi- MMP-2 is not mediated by serine proteases, such as
gene family of over 25 secreted and cell surface enzymes plasmin, as is the case for other MMPs. Instead, protease
inhibitor studies suggest that MMP-2 is activated by met-that are capable of degrading a variety of ECM compo-
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Fig. 7. Interstitial disease in X-linked Alport syndrome (XLAS) is associated with elevated matrix metalloproteinases (MMP-2 and MMP-9)
mRNA transcripts. (A ) Reverse transcription polymerase chain reaction (RT-PCR) from RNA isolated from normal and XLAS dog kidneys
using primers specific for MMP-2, MMP-9, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Lanes 1 to 3, mRNA expression from
normal unaffected dogs. Lanes 4 to 8, mRNA expression from XLAS dogs. GAPDH mRNA levels were also analyzed as a control for loading.
(B ) Semiquantification of mRNA transcripts for MMPs was performed using densitometry and normalized to GAPDH from the same sample.
The results are presented as an index of mRNA expression (arbitrary units). Data are presented as the mean and standard deviation for three
independent experiments. (C ) The mean and standard deviation across groups of normal and Alport samples for three independent experiments.
*Statistical significance compared with control samples (P 	 0.001).
alloproteinases themselves and requires interaction with that clustering of cell surface molecules can lead to in-
creased expression of active MMP-2. In the presentcell surface proteins [30, 31]. This unique property of
MMP-2 activation likely directs proteolytic activity to study, we analyzed the expression of mRNA transcripts
for MT1-MMP and found them to be significantly ele-either migrating cells or cells involved in ECM turnover.
Recently, the membrane-bound MT1-MMP has been vated in XLAS dogs compared to controls. The balance
between TIMP-2 and MT1-MMP may be critical for de-identified as a potential physiologic activator of MMP-2
on the cell surface. Studies have shown that a complex termining the activation status of MMP-2. Our studies
show that the active form of MMP-2, while abundant inof MT1-MMP mediates activation of proMMP-2 with
TIMP-2, acting as a surface receptor for proMMP-2 XLAS renal cortex, is absent in controls. The absence of
active MMP-2 in controls may be explained by relatively[32–34]. In cell culture, MT1-MMP expression can be
stimulated by the lectin, concanavalin A [23], suggesting decreased activation of MT1-MMP, due to incomplete
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Fig. 8. Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) mRNA transcripts in X-linked Alport syndrome (XLAS). (A )
Shows reverse transcription polymerase chain reaction (RT-PCR) from RNA isolated from normal and XLAS dog kidneys using primers specific
for MT1-MMP and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Lanes 1 to 3, mRNA expression from normal unaffected dogs. Lanes
4 to 8, mRNA expression from XLAS dogs. (B ) Semiquantification of mRNA transcripts for MT1-MMP was performed using densitometry and
comparison to GAPDH as done in Figure 6. Data is presented as the mean and standard deviation for three independent experiments. (C ) The
mean and standard deviation across groups of normal and Alport samples for three independent experiments. *Statistical significance compared
with control samples (P 	 0.001).
processing of pro-MT1-MMP to its active form, instabil- In the present study we show that MMP-9 activity was
significantly increased in XLAS. Of the total detectedity of the MT1-MMP protein, or lack of translation of
MT1-MMP mRNA into protein. It has been shown that MMP-9, about 35% represented active MMP-9, sug-
gesting that the activation of MMP-9 in XLAS is signifi-proteolytic cleavage of pro-MT1-MMP is a prerequisite
for pro-MMP-2 activation [35, 36]. cantly higher than active MMP-2. Recent studies have
shown that the mRNA transcripts for MMP-3 and MMP-7A large number of proteases and organomercurials
have been shown to activate other MMPs in vitro; how- were significantly increased in XLAS kidneys (Rao and
Cosgrove, unpublished). Therefore, it appears that MT1-ever, the mechanisms of activation are not well docu-
mented in vivo. A potentially important mechanism for MMP, MMP-7, and MMP-3 likely participates in MMP-2
and MMP-9 activation in this model. The coexpressionactivation of latent MMPs is intermolecular activation.
Both MMP-3 and MMP-10 are good activators of MMP-7 of MMP-2, MMP-3, MMP-7, and MMP-9 may function
as powerful machinery for ECM degradation in XLAS[37, 38]. MMP-3 can fully cleave pro-MMP-7 to generate
an active species [37]. MMP-7 has been shown to activate kidneys.
The common pathway of progressive tubulointerstitialhuman MMP-1, MMP-2, and MMP-9 [37, 39, 40]. It has
been reported that MT1-MMP can activate collagenase 3 fibrosis is the end result for most acute and progressive
renal disease. The process of interstitial scarring and(MMP-13) and MMP-9 [41]. In addition, pro-MMP-9 can
be activated by gelatinase A (MMP-2) [42], MMP-3 [43], cellular destruction associated with interstitial fibrosis
shares many characteristics from one organ to another.MMP-13 [44], plasmin [45], and tissue kallikrein [46].
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